Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $362.7 million.

  • Amylyx Pharmaceuticals' Liabilities and Shareholders Equity rose 4468.38% to $362.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $970.6 million, marking a year-over-year decrease of 3604.84%. This contributed to the annual value of $193.6 million for FY2024, which is 6257.95% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Liabilities and Shareholders Equity of $362.7 million as of Q3 2025, which was up 4468.38% from $194.6 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $517.5 million in Q4 2023 and a low of $105.6 million during Q4 2021
  • Its 5-year average for Liabilities and Shareholders Equity is $312.2 million, with a median of $303.3 million in 2022.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Liabilities and Shareholders Equity surged by 27064.5% in 2022, and later tumbled by 6257.95% in 2024.
  • Amylyx Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $105.6 million in 2021, then surged by 270.64% to $391.5 million in 2022, then surged by 32.19% to $517.5 million in 2023, then crashed by 62.58% to $193.6 million in 2024, then surged by 87.33% to $362.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $362.7 million for Q3 2025, versus $194.6 million for Q2 2025 and $219.7 million for Q1 2025.